Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as ...
